» Articles » PMID: 25944705

Prices and Mark-ups on Antimalarials: Evidence from Nationally Representative Studies in Six Malaria-endemic Countries

Abstract

The private for-profit sector is an important source of treatment for malaria. However, private patients face high prices for the recommended treatment for uncomplicated malaria, artemisinin combination therapies (ACTs), which makes them more likely to receive cheaper, less effective non-artemisinin therapies (nATs). This study seeks to better understand consumer antimalarial prices by documenting and exploring the pricing behaviour of retailers and wholesalers. Using data collected in 2009-10, we present survey estimates of antimalarial retail prices, and wholesale- and retail-level price mark-ups from six countries (Benin, Cambodia, the Democratic Republic of Congo, Nigeria, Uganda and Zambia), along with qualitative findings on factors affecting pricing decisions. Retail prices were lowest for nATs, followed by ACTs and artemisinin monotherapies (AMTs). Retailers applied the highest percentage mark-ups on nATs (range: 40% in Nigeria to 100% in Cambodia and Zambia), whereas mark-ups on ACTs (range: 22% in Nigeria to 71% in Zambia) and AMTs (range: 22% in Nigeria to 50% in Uganda) were similar in magnitude, but lower than those applied to nATs. Wholesale mark-ups were generally lower than those at retail level, and were similar across antimalarial categories in most countries. When setting prices wholesalers and retailers commonly considered supplier prices, prevailing market prices, product availability, product characteristics and the costs related to transporting goods, staff salaries and maintaining a property. Price discounts were regularly used to encourage sales and were sometimes used by wholesalers to reward long-term customers. Pricing constraints existed only in Benin where wholesaler and retailer mark-ups are regulated; however, unlicensed drug vendors based in open-air markets did not adhere to the pricing regime. These findings indicate that mark-ups on antimalarials are reasonable. Therefore, improving ACT affordability would be most readily achieved by interventions that reduce commodity prices for retailers, such as ACT subsidies, pooled purchasing mechanisms and cost-effective strategies to increase the distribution coverage area of wholesalers.

Citing Articles

An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries.

Leon G, Carbonel C, Rampuria A, Rajpoot R, Joshi P, Kanavos P Eur J Health Econ. 2024; .

PMID: 39299943 DOI: 10.1007/s10198-024-01706-x.


Access to quality-assured artemisinin-based combination therapy and associated factors among clients of selected private drug outlets in Uganda.

Ocan M, Nakalembe L, Otike C, Mordecai T, Birungi J, Nsobya S Malar J. 2024; 23(1):128.

PMID: 38689257 PMC: 11059854. DOI: 10.1186/s12936-024-04956-5.


Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.

Ocan M, Nambatya W, Otike C, Nakalembe L, Nsobya S PLoS One. 2024; 19(3):e0295198.

PMID: 38536824 PMC: 10971760. DOI: 10.1371/journal.pone.0295198.


Optimal control analysis of hepatocytic-erythrocytic dynamics of malaria.

Orwa T, Mbogo R, Luboobi L Infect Dis Model. 2022; 7(1):82-108.

PMID: 34977436 PMC: 8686038. DOI: 10.1016/j.idm.2021.11.006.


To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?.

de Haan F, Bolarinwa O, Guissou R, Tou F, Tindana P, Boon W PLoS One. 2021; 16(8):e0256567.

PMID: 34464398 PMC: 8407563. DOI: 10.1371/journal.pone.0256567.


References
1.
Laxminarayan R, Gelband H . A global subsidy: key to affordable drugs for malaria?. Health Aff (Millwood). 2009; 28(4):949-61. DOI: 10.1377/hlthaff.28.4.949. View

2.
Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Kleinschmidt I . Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries. PLoS One. 2014; 9(4):e93763. PMC: 3974780. DOI: 10.1371/journal.pone.0093763. View

3.
Dondorp A, Nosten F, Yi P, Das D, Phyo A, Tarning J . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5):455-67. PMC: 3495232. DOI: 10.1056/NEJMoa0808859. View

4.
Nakamba P, Hanson K, McPake B . Markets for hospital services in Zambia. Int J Health Plann Manage. 2002; 17(3):229-47. DOI: 10.1002/hpm.673. View

5.
Conteh L, Hanson K . Methods for studying private sector supply of public health products in developing countries: a conceptual framework and review. Soc Sci Med. 2003; 57(7):1147-61. DOI: 10.1016/s0277-9536(02)00491-4. View